Celltrion, Inc.

KOSE:A068270 Stock Report

Market Cap: ₩37.4t

Celltrion Valuation

Is A068270 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of A068270 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: A068270 (₩170300) is trading below our estimate of future cash flow value (₩178091.97)

Significantly Below Future Cash Flow Value: A068270 is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A068270?

Key metric: As A068270 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A068270. This is calculated by dividing A068270's market cap by their current earnings.
What is A068270's PE Ratio?
PE Ratio29.5x
Earnings₩1.27t
Market Cap₩37.43t

Price to Earnings Ratio vs Peers

How does A068270's PE Ratio compare to its peers?

The above table shows the PE ratio for A068270 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.2x
A196170 ALTEOGEN
145.4x44.25%₩18.9t
A0126Z0 Samsung Epis Holdings
20.9x-9.40%₩10.7t
A214450 PharmaResearch
17.3x20.38%₩3.1t
A145020 Hugel
17.3x25.29%₩2.6t
A068270 Celltrion
29.5x15.92%₩37.4t

Price-To-Earnings vs Peers: A068270 is good value based on its Price-To-Earnings Ratio (29.5x) compared to the peer average (50.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does A068270's PE Ratio compare vs other companies in the KR Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
A068270 29.5xIndustry Avg. 27.7xNo. of Companies4PE01632486480+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A068270 is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the KR Biotechs industry average (27.7x).

Price to Earnings Ratio vs Fair Ratio

What is A068270's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A068270 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.5x
Fair PE Ratio25.1x

Price-To-Earnings vs Fair Ratio: A068270 is expensive based on its Price-To-Earnings Ratio (29.5x) compared to the estimated Fair Price-To-Earnings Ratio (25.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A068270 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩170,300.00
₩254,025.79
+49.16%
7.37%₩280,000.00₩190,476.19n/a24
Jun ’27₩182,571.43
₩252,698.41
+38.41%
7.72%₩276,190.48₩190,476.19n/a24
May ’27₩190,952.38
₩247,950.31
+29.85%
7.82%₩276,190.48₩190,476.19n/a23
Apr ’27₩196,190.48
₩240,793.65
+22.73%
10.25%₩276,190.48₩161,904.76n/a24
Mar ’27₩227,142.86
₩241,865.08
+6.48%
10.34%₩276,190.48₩161,904.76n/a24
Feb ’27₩200,000.00
₩225,529.57
+12.76%
11.36%₩261,904.76₩142,857.14n/a23
Jan ’27₩172,380.95
₩215,414.61
+24.96%
11.05%₩238,095.24₩142,857.14n/a22
Dec ’26₩176,952.38
₩212,817.21
+20.27%
10.68%₩238,095.24₩142,857.14n/a22
Nov ’26₩167,238.10
₩210,095.96
+25.63%
11.44%₩238,095.24₩133,333.33n/a21
Oct ’26₩166,761.90
₩209,007.03
+25.33%
12.50%₩238,095.24₩133,333.33n/a23
Sep ’26₩161,714.29
₩208,500.58
+28.93%
12.47%₩238,095.24₩133,333.33n/a23
Aug ’26₩163,142.86
₩207,438.42
+27.15%
11.22%₩238,095.24₩133,333.33n/a22
Jul ’26₩152,761.90
₩204,516.32
+33.88%
11.27%₩238,095.24₩128,205.13n/a22
Jun ’26₩147,435.90
₩206,916.10
+40.34%
10.14%₩238,095.24₩128,205.13₩182,571.4321
May ’26₩147,710.62
₩215,997.30
+46.23%
11.73%₩261,643.12₩137,362.64₩190,952.3820
Apr ’26₩160,073.26
₩216,966.52
+35.54%
11.45%₩261,643.12₩137,362.64₩196,190.4821
Mar ’26₩168,498.17
₩217,631.01
+29.16%
11.39%₩261,643.12₩137,362.64₩227,142.8621
Feb ’26₩164,560.44
₩216,218.97
+31.39%
11.06%₩261,643.12₩139,543.00₩200,000.0021
Jan ’26₩171,703.30
₩215,336.44
+25.41%
11.53%₩261,643.12₩139,543.00₩172,380.9521
Dec ’25₩163,090.88
₩214,132.05
+31.30%
13.22%₩261,643.12₩139,543.00₩176,952.3821
Nov ’25₩157,945.23
₩216,016.23
+36.77%
14.28%₩270,364.56₩130,821.56₩167,238.1019
Oct ’25₩170,416.88
₩216,934.28
+27.30%
13.32%₩270,364.56₩130,821.56₩166,761.9019
Sep ’25₩177,045.18
₩216,291.64
+22.17%
13.97%₩270,364.56₩130,821.56₩161,714.2919
Aug ’25₩174,428.75
₩208,878.42
+19.75%
14.62%₩261,643.12₩130,821.56₩163,142.8616
Jul ’25₩160,561.66
₩204,286.84
+27.23%
14.63%₩261,643.12₩130,821.56₩152,761.9017
Jun ’25₩153,671.73
₩202,234.74
+31.60%
12.47%₩261,643.12₩150,008.72₩147,435.9017
₩254.03k
Fair Value
33.0% undervalued intrinsic discount
24
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/21 21:45
End of Day Share Price 2026/06/19 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Celltrion, Inc. is covered by 41 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Girish BakhruBofA Global Research
Dae Woong YooBookook Securities Co. Ltd
Hyeryeong KimCGS International